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ABSTRACT
M2 macrophages promote tumor growth and metastasis, but their interactions 
with specific tumor cell populations are poorly characterized. Using a mouse model of 
spontaneous melanoma, we showed that CD34- but not CD34+ tumor-initiating cells 
(TICs) depend on M2 macrophages for survival and proliferation. Tumor-associated 
macrophages (TAMs) and macrophage-conditioned media protected CD34- TICs from 
chemotherapy in vitro. In vivo, while inhibition of CD115 suppressed the macrophage-
dependent CD34- TIC population, chemotherapy accelerated its development. The 
ability of TICs to respond to TAMs was acquired during melanoma progression and 
immediately preceded a surge in metastatic outgrowth. TAM-derived transforming 
growth factor-β (TGFβ) and polyamines produced via the Arginase pathway were 
critical for stimulation of TICs and synergized to promote their growth.
INTRODUCTION
Tumor initiating cells (TICs) are stem-like cells 
with the ability to initiate tumor growth and contribute 
to common properties of tumors, including resistance to 
chemotherapy, recurrence following initial remission, 
cellular heterogeneity, and metastasis. Thus, a better 
understanding of the biology of TIC is essential to advance 
the development of novel therapies. In the past decade, 
the intimate relationship between the immune system and 
tumor progression has been recognized. Several studies 
have revealed possible interactions between TICs and 
immune cell populations; for example TICs can activate 
immune-suppressive T regulatory cells [1, 2], while CD8+ 
T cells support the development of TICs in breast cancer 
[3]. 
Macrophages can be broadly divided into two 
subtypes, M1 and M2 [4]. M1 cells are involved in 
pathogen clearance and pro-inflammatory responses while 
M2 cells are anti-inflammatory, promote tissue remodeling 
and are associated with tumor progression [5]. Recent 
studies in mice transplanted with human cancer cell lines, 
provided some evidence that TIC-mediated tumorigenesis 
and chemoresistance are supported by tumor-associated 
macrophages (TAMs) [6-8]. While transplanted models 
are a useful tool to study TICs in human cell lines, there 
are limitations in their ability to mimic natural tumor 
progression and the complexity of the tumor niche. 
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Transplanted tumors generally develop rapidly, within 
days or weeks, compared to the much slower progression, 
months to years, observed in humans. Consequently, the 
composition of tumor cells, stromal cells and immune 
cells within transplanted tumors and their interactions may 
differ significantly from spontaneous tumors that develop 
over a prolonged period of time.
Immune-competent RETAAD mice express the 
human RET oncogene in melanocytes, resulting in uveal 
melanomas starting from two to three weeks of age, 
followed by distant metastasis. Although disseminated 
tumor cells are detected throughout the body from three 
weeks of age, metastatic outgrowth is delayed by the 
immune system. The median time for onset of metastatic 
growth are 66 days (facial), 80 days (neck/trunk), 242 days 
(reproductive tract) 263 days (mediastinum) and 347 days 
(lungs) respectively [9]. Thus the TIC-immune interaction 
might be a critical determinant of tumor cell quiescence, 
proliferation or metastasis. These mice provide a unique 
opportunity to study the spontaneous initiation and 
progression of cancer that recapitulate many features of 
human disease. 
In this study we employed this clinically-relevant 
RETAAD model to analyze the interactions between 
TICs and TAMs in spontaneous melanomas. TICs can be 
detected by culturing dissociated tumor cells in a defined 
serum-free medium to form free-floating colonies similar 
to the neurosphere assay [10]. The tumor sphere culture 
has been used to enrich for TICs in many types of cancer 
including melanoma [11, 12], colon cancer [13], lung 
cancer [14] and breast cancer [15]. These authors have 
showed that cells from tumor spheres not only have more 
stem cell properties but also initiate tumors in vivo more 
efficiently than their adherent counterparts. Each colony, 
referred to as a melanosphere in the case of melanoma, is 
assumed to originate from a single TIC. Using this assay 
we seek to determine whether TAMs interact with TICs 
and how do these interactions affect tumor progression 
and response to chemotherapy? What are the underlying 
molecular mechanisms and pathways? And can we identify 
any opportunity for novel therapeutic interventions that 
target TIC-TAM interactions?
RESULTS
RETAAD tumors contain multiple tumorigenic 
cell subsets
Using the sphere forming assay we first established 
that cells from the primary eye tumor forms melanospheres 
in culture. Consistent with the expected stem cell property 
of sphere-forming cells, the melanospheres could 
be passaged at least twice in culture, while retaining 
expression of the melanoma antigen S100B (Figure 1A).
The phenotype of murine TICs is incompletely defined. 
Following the work of Held et al. [16], we studied the 
tumor cell populations expressing the melanocytic stem/
progenitor cell marker CD34, and CD271, a neural crest 
stem cell marker. Unlike the previous study, RETAAD 
tumor cells could not be clearly separated using these two 
markers (Figure 1B). Therefore we isolated cells at the 
extreme end of the expression spectrum for each marker 
and compared their sphere-forming ability. Ninety-five 
percent of the RETAAD tumor cells were CD34- CD271- 
(hereafter denoted as CD34-), while the CD34 and CD271 
single positive populations accounted for less than one 
percent. We did not observe a distinct double positive 
population. The CD34+ population formed significantly 
larger spheres and with higher efficiency than the CD34- 
cells (Figure 1C to E). The CD271+ population formed 
very few spheres (Figure 1E), and therefore was not 
analyzed further. To determine whether the CD34- and 
CD34+ sphere-forming cells could initiate tumors in vivo, 
we inoculated Rag1 mice with 100 spheres from either 
CD34- or CD34+ tumor cells via the retro-orbital sinus, 
delivering them directly to the lungs. Despite differences 
in in vitro sphere-forming assays, both types of spheres 
initiated tumors in vivo (Figure 1F) with similar efficiency 
(Figure 1G) and growth rate (Figure 1H).
The CD34- population includes TICs that respond 
to immune cell stimulation
Based on the emerging evidence of interactions 
between immune cells and TICs, we asked whether tumor-
associated immune cells affect the ability of the TICs to 
form spheres in culture. We purified CD45+ immune cells 
from tumors and added them to TICs in sphere cultures at 
a ratio of 1:50, corresponding to their relative abundance 
in RETAAD tumors in vivo [17]. CD45+ cells cultured 
alone in melanosphere medium did not form spheres 
(Figure 2A). Adding CD45+ cells to unsorted tumor cells 
led to a slight increase in efficiency of sphere formation 
(P0 spheres) (Figure 2B). Similarly, dissociated cells from 
untreated P0 spheres continued to increase their sphere-
formation efficiency in response to CD45+ cells (Figure 
2C), implying that the immune-responsive TICs were 
maintained during passage. We then determined whether 
immune cells were involved in the normal maintenance 
of the TICs by depleting CD45+ cells from dissociated 
tumor cell preparations. The absence of CD45+ cells led 
to a significant reduction in sphere formation efficiency, 
which was rescued by re-addition of purified CD45+ cells 
(Figure 2D). As sphere formation was reduced, but not 
abrogated by the loss of CD45+ cells, we conclude that a 
proportion of the TICs in RETAAD tumors is dependent 
on immune cells for survival. To identify this population 
we compared the effect of CD45+ cells on the ability of 
CD34- and CD34+ TIC sub-populations to form spheres 
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in vitro, and found that only the CD34- TICs responded 
to the addition of CD45+ cells (Figure 2E). In addition to 
increasing the efficiency of CD34- TIC sphere formation, 
CD45+ cells also significantly increased sphere size 
(Figure 2F). Thus CD45+ cells promote both melanosphere 
initiation and proliferation.
TAMs with M2-like properties stimulate 
melanosphere formation by CD34- TICs
Amongst CD45+ immune cells, macrophages are 
known to promote tumor cell proliferation and migration 
[18]. To determine whether macrophages are involved in 
stimulating sphere formation by CD34- TICs, we isolated 
CD11b+CD68+ TAMs (Supplemental Figure S1C for 
morphology) from RETAAD tumors using flow cytometry 
(Figure 3A) and co-cultured them with CD34- TICs in 
the sphere-forming assay. TAMs significantly increased 
sphere formation by CD34- TICs (more than two folds), 
while CD11b+CD68- myeloid cells had no effect (Figure 
3B). T, B and NK cells within the Lin+ gate also have no 
stimulatory effect whether as a mixed population (Figure 
3B) or as separate populations (Supplemental Figure S1A 
and B).
To confirm the role of TAMs in in vitro sphere 
formation by TICs we next inhibited the colony 
stimulatory factor-1 receptor (CSF-1R or CD115), which 
is required for macrophage survival and polarization [19, 
20]. Using two CD115 inhibitors, the tyrosine kinase 
inhibitor Ki20227 and a neutralizing antibody, we showed 
that blocking CD115 in vitro abolishes the stimulatory 
effect of TAMs on sphere formation by CD34- TICs, but 
does not affect sphere formation in the absence of TAMs 
(Figure 3C). To exclude the possibility that CD115 may be 
present on the tumor cells and contribute to the observed 
Figure 1: Characteristics of melanoma sub-populations in the RETAAD tumor. Statistical analysis: ***P < 0.001, **** P 
< 0.0001, N.S. not significant. (A) Melanospheres labeled for S100B (red) and Ki67 (blue). (B) Flow cytometry with CD34 and CD271 
antibodies did not reveal distinct populations. Three populations were selected as shown. (C) Brightfield images of spheres cultured 
from CD34-CD271- and CD34+ cells. Scale bar equals 50µm. (D) Graph comparing the size of CD34- and CD34+ spheres. Bars represent 
geometric mean ± 95% CI, two-tailed Mann-Whitney test. (E) Graph showing sphere-forming efficiency (percentage of seeded cells that 
formed spheres) from selected tumor cell populations indicated in B. Bars represent mean ± SD, 1-way ANOVA. (F) CD34- and CD34+ 
spheres initiate tumors in the lungs of Rag1 mice. Left panel, IHC staining to illustrate lung morphology and CD34- sphere initiated tumor 
labeled for S100B (red). Right panel, fluorescence staining to show localization of CD34+ sphere initiated tumor labeled for S100B (green), 
CD45+ cells (white), CD68+ cells (red) and nuclei (blue). Scale bars equal 50µm. (G) Comparison of number of tumor nodule presented in 
F. Twenty lung sections were sampled from each mouse. Each point represent one mouse, Wilcoxon matched-pairs signed rank test. (H) 
Comparison of size of tumor nodules presented in F. Bars represent geometric mean ± 95% CI, two-tailed Mann-Whitney test.
Oncotarget4www.impactjournals.com/oncotarget
effects, we pre-treated the tumor cells with anti-CD115 
antibody before stimulating them with TAMs. This did 
not inhibit the stimulatory effect of TAMs (Supplemental 
Figure S1D). Conversely, pre-treatment of TAMs with 
anti-CD115 antibody before adding them to the tumor 
cells completely abrogated their stimulatory effect 
(Supplemental Figure S1E). In addition, qPCR confirmed 
that the CD34- tumor cells express negligible levels of 
CD115 compared to the TAMs (Supplemental Figure 
S1F), and CD115 immunolabeling within tumor sections 
was accordingly restricted to immune cells (Supplemental 
Figure S1G). Together these data demonstrate that CD115 
inhibition prevents TAMs from stimulating sphere 
formation by the CD34- TIC population within RETAAD 
primary melanomas.
Two recent publications has shown that cancer-
associated fibroblasts (CAF) can promote stemness in 
prostate cancer cells [21] and that CAF can synergize with 
M2 macrophages to promote tumor invasiveness [22]. 
Since the CD34- tumor population in our study will also 
include the fibroblasts and endothelial cells it is possible 
that the observed sphere stimulatory effects of TAMs may 
involve interactions with CAFs. To exclude this possibility 
we removed the CD45- CAF based on Platelet Derived 
Growth Factor Receptor (PDGFR)α expression [23] and 
the CD45- endothelial cells based on CD31 expression 
(Supplemental Figure S2A). Removal of these stromal 
cells did not alter the melanosphere formation efficiency 
Figure 2: CD45+ immune cells stimulate melanosphere formation. For panels B to E, data are expressed as fold change in 
sphere-forming efficiency relative to untreated or unsorted cells as indicated on the y-axis. Bars represent mean ± SE, * P < 0.05, **P < 
0.01, **** P < 0.0001, N.S. not significant. (A) Brightfield image of CD45+ cells cultured alone in stem cell medium for 5 days. (B) Passage 
0: Freshly isolated unsorted tumor cells were cultured with or without CD45+ immune cells isolated from tumors, two-tailed Mann-Whitney 
test. (C) Passage 1: Untreated P0 spheres were dissociated and recultured with or without CD45+ immune cells isolated from tumors, two-
tailed Mann-Whitney test. (D) Graph comparing sphere-forming efficiency of untreated tumor cells, tumor cell preparations with CD45+ 
cells removed (deplete) and CD45-depleted tumor cell preparations with CD45+ cells added back (D+CD45), 1-way ANOVA. (E) Graph 
comparing sphere-forming efficiency from sorted CD34- and CD34+ TICs cultured with or without CD45+ cells, 2-way ANOVA. (F) Effect 
of CD45+ cells on the size of CD34- spheres. Bars represent geometric mean ± 95% CI, two-tailed Mann-Whitney test.
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(Supplemental Figure S2B) or affected the stimulatory 
effect of the TAMs on sphere formation and sphere 
proliferation (Supplemental Figure S2C and D). Since 
these stromal cells do not contribute to the ability of TAMs 
to stimulate sphere formation by the CD34- TICs we did 
not eliminate them from subsequent experiments.
To gain insight into the mechanisms underlying 
TIC stimulation by macrophages, we analyzed the 
cytokine profiles of TAMs. Similar to other models [24], 
TAMs isolated from RETAAD tumors exhibited a gene 
expression pattern consistent with M2 macrophages 
including high expression of transforming growth factor-β 
(Tgfb1), arginase 1 (Arg1) and Fizz1 (Supplemental Figure 
S3A), with lower levels of M1-related genes such as 
nitric oxide synthase 2 (Nos2), interleukin-12 (Il12) and 
interleukin-1β (Il1b) (Supplemental Figure S3B). These 
TAMs also express the M2 macrophage marker CD206 
(Supplemental Figure S3C). Thus we hypothesized that 
M2-like macrophages could stimulate melanosphere 
formation. To test this hypothesis, we polarized bone 
marrow-derived macrophages (BMDM) towards either 
the M1- or M2-phenotype using LPS and IFNγ, or IL-4 
Figure 3: TAMs stimulate melanosphere formation. Data for all bar graphs are expressed as fold change in sphere-forming 
efficiency relative to untreated CD34- TICs. Bars represent mean ± SE, * P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001, N.S. not 
significant, 1-way ANOVA for B and D to F, 2-way ANOVA for C. (A) Flow cytometry sorting of immune cell populations. The Lin+ gate 
contain T, B and NK cells. Lin- cells are separated into CD11b+CD68- myeloid cells and CD11b+CD68+ TAMs. (B) Effect of immune cell 
populations on sphere formation: CD34- TICs were cultured with the immune cell populations sorted in A. (C) Effect of TAM inhibition on 
sphere formation: CD34- TICs were cultured with or without TAMs. Two CSF1R inhibitors Ki20227 (Ki; 100nM) and CD115-neutralizing 
antibody (α-CD115; 1µg/ml) were added for the duration of the culture. (D) Effect of BMDM on sphere formation: BMDM from tumor-
bearing mice (RET+) and non-tumor bearing littermates (ret-) were polarized to M1 or M2 phenotype and co-cultured with CD34- TICs. (E) 
Effect of conditioned medium (CM) on sphere formation: CM generated from M1- or M2-polarized BMDM were added to CD34- TICs at 
1/10th of stem cell media volume. (F) Effect of CSF1R inhibitors on the stimulatory effect of M2-BMDM CM (M2-CM): Ki20227 (100nM) 
and anti-CD115 (1µg/ml) were either added to the BMDM prior to CM generation (Ki20227 > CM, α-CD115 > CM) or added to the CM 
during sphere culture (CM+Ki20227, CM+α-CD115). 
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respectively. M2-BMDM from both tumor-bearing (RET+) 
mice and non-tumor bearing (ret-) littermates stimulated 
sphere formation, while the M1 macrophages had minimal 
activity (Figure 3D). Furthermore, conditioned medium 
generated from M2-BMDM (M2-CM) stimulated sphere 
formation while M1-conditioned medium (M1-CM) 
did not (Figure 3E). Pre-treatment of M2-BMDM with 
Ki20227 or anti-CD115 antibody before generating CM 
removed the stimulatory effect of CM, whereas direct 
addition of these inhibitors to the CM during sphere 
culture had minimal effect (Figure 3F). This shows that 
activated M2-like macrophages derived from either tumor-
bearing or wild-type mice stimulate sphere formation by 
CD34- TICs.
The onset of CD34- TIC responsiveness to TAM 
stimulation correlates with disease progression in 
vivo
Having observed the potent effects of TAMs on 
RETAAD TICs in vitro it seemed plausible that TAM-
mediated TIC stimulation might play a role in melanoma 
progression. We first compared the responses of TICs to 
TAM stimulation using cells isolated from mice at various 
stages of disease progression. Interestingly, the CD34- 
TICs isolated from young mice (< 30 weeks) with less 
advanced disease formed spheres with equal efficiency 
in the presence or absence of TAMs, while TICs from 
mice over 30 weeks of age was strongly stimulated by 
TAMs (Figure 4A). This phenomenon was driven by the 
TIC population rather than the TAMs, as “young” TICs 
similarly failed to respond to “old” TAMs isolated from 
mice with advanced disease, while TICs from older 
Figure 4: Acquisition of macrophage responsiveness by TICs coincides with tumor progression. Statistical analysis: * P < 
0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001, N.S. not significant. (A) CD34- TICs from old (>30 week) or young (<30 week) mice were 
cultured with TAMs derived from old or young mice. Data are expressed as fold change in sphere formation efficiency relative to untreated 
CD34- TICs. Bars represent mean ± SE, 2-way ANOVA. (B) Percentage of macrophage stimulation of sphere formation from CD34- cells 
from mice of different age groups, reflecting stage of disease. TAMs were donor-matched to the CD34- TICs. Each point represents one 
mouse, 1-way ANOVA. (C) Graph comparing sphere-forming efficiency of unsorted cells and CD34- TICs from mice of different age 
groups. Bars represent mean ± SD, 2-way ANOVA. (D) Graph showing the number of macroscopic tumors detected in mice of different 
ages on the left axis. Each point represents one mouse (total 285 mice). Black line is the percentage of mice (right axis) that have more than 
21 tumors (80th percentile). One-way ANOVA.
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mice responded to TAMs from mice with early or late 
disease (Figure 4A). As shown in Figure 4B, CD34- TIC 
responsiveness to TAMs began at 30 weeks of mouse 
age, peaked in mice aged between 45 and 50 weeks and 
then slightly decreased in mice above 50 weeks of age. 
Importantly, the total number of CD34- TICs did not 
change significantly with age across the analyzed period 
(20 to 50 weeks) but rather a subpopulation of these TICs 
became responsive to TAMs after 30 weeks (Figure 4C). In 
order to understand the significance of this change in vivo 
we compared the timeline of in vitro TIC responsiveness 
to TAM stimulation retrospectively with necropsy data of 
tumor burden in mice aged 1-69 weeks. The acquisition 
of TAM-responsiveness from 30 weeks of mouse age 
immediately preceded a sharp increase in the percentage 
of mice having a large number of tumors (Figure 4D): 
50% of the mice analyzed between 35 and 39 weeks of age 
had more than 21 macroscopic metastases (80th percentile 
for tumor burden). The percentage of mice with more than 
21 macroscopic metastases had a biphasic pattern (Figure 
4D), implying the presence of two sub-populations of 
mice with early and late tumor development. Taken 
together, these results suggest that late on during disease 
progression (after 30 weeks of age) a sub-population of 
CD34- TICs either arises or acquires the ability to respond 
to TAM stimulation, and so may contribute to the sudden 
outgrowth of a proportion of metastases at around 30 
weeks of age, while those tumors developing before this 
time are likely originating from TICs that are independent 
of TAMs for survival and growth.
Figure 5: Macrophages support TIC survival in vivo. Data for D to F are expressed as fold change in sphere-forming efficiency 
relative to untreated CD34- TICs. Statistical analysis: **P < 0.01, **** P < 0.0001, N.S. not significant. (A) Principle Component Analysis 
(PCA) mapped scatter plot: The global gene expression profiles of untreated (red) or M2-CM treated CD34- spheres (green) and CD34+ 
spheres (black) were analyzed by PCA. Graph represents the first three principal components of the microarray analysis data (PC1, PC2 and 
PC3) in the X, Y and Z axis respectively. (B) Comparison of number of tumor nodules formed in lungs of Rag1 mice injected with CD34- 
spheres derived from untreated, M2-CM- or TAM-stimulated cultures. Twenty lung sections were sampled from each mouse. Each point 
represent one mouse, Wilcoxon matched-pairs signed rank test. (C) Comparison of size of the tumor nodules presented in B. Bars represent 
geometric mean ± 95% CI, 1-way ANOVA. (D) Effect of in vivo CD115 inhibition on sphere formation in vitro: CD34- TICs from mice 
treated with vehicle, Ki20227 or anti-CD115 for 10 days were cultured with or without TAMs from untreated mice. Bars represent mean ± 
SE, 2-way ANOVA. (E) Effect of in vivo CD115 inhibition on TAM activity in vitro: CD34- TICs from untreated mice were cultured with 
TAMs from untreated (+UT) mice, or mice treated with vehicle (+Veh), Ki20227 for 10 days (+Ki) or Ki20227 for 10 days followed by 
10 days recovery [+Ki (re)] mice. Bars represent mean ± SE, 1-way ANOVA. (F) Recovery of macrophage-responsive TICs: CD34- TICs 
from vehicle-, Ki20227- or Ki20227 recovery- treated mice were cultured with or without TAMs from untreated mice. Bars represent mean 
± SE, 2-way ANOVA.
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TAMs support CD34- TIC survival in vivo
Our data show that TAMs can support CD34- 
TIC survival and proliferation in vitro and that in vivo 
this may translate into increased tumor burden in older 
RETAAD mice. Therefore we asked whether the TAMs 
were mediating their effect on TICs by inducing changes 
in gene expression. Microarray comparison of TAM-
stimulated and non-stimulated CD34- melanospheres 
revealed comparable patterns of expression, whereas the 
CD34+ spheres had a distinct transcriptome, as shown by 
principal component analysis (Figure 5A). In particular 
TAM stimulation did not increase the expression of 
CD34 in the CD34- spheres (Supplementary Figure S4), 
indicating that the TAM-stimulated CD34- spheres are 
not becoming CD34+ spheres. When the same number of 
TAM-stimulated and non-stimulated CD34- spheres were 
transplanted in vivo they initiated tumors in the lungs with 
similar efficiency and of similar size (Figure 5B and C). 
This indicated that TAMs increase CD34- TIC survival 
(sphere formation) without altering their tumorigenic 
potential. To determine whether CD34- TICs depend on 
macrophages for survival in vivo, we treated mice with 
Ki20227 or anti-CD115 antibody for 10 days. CD34- 
TICs were isolated from treated mice and cultured with 
TAMs from untreated animals, but CD115 inhibition had 
rendered them unable to respond to TAM stimulation of 
sphere formation (Figure 5D). To understand how CD115 
inhibition in vivo abolished TIC responsiveness to TAMs 
in vitro, we isolated TAMs from inhibitor-treated mice and 
asked whether they could stimulate TICs from untreated 
mice. Ki20227 treatment did not reduce the number of 
CD68+ TAMs, (Supplemental Figure S5A) but significantly 
inhibited their sphere-stimulatory activity (Figure 5E). In 
contrast, treatment with anti-CD115 antibody reduced the 
number of TAMs by 50% (Supplemental Figure S5B), but 
did not affect the TIC-stimulatory activity of the residual 
TAMs (Supplemental Figure S5C). Taken together, these 
data demonstrate that a sub-population of CD34- TICs 
depends on TAMs for survival in vivo, such that inhibition 
of TAM activity or reduction of TAM numbers causes the 
Figure 6: Chemotherapy promotes the emergence of macrophage-responsive TICs. Data for C & D are expressed as fold 
change in sphere-forming efficiency relative to untreated CD34- TICs. Statistical analysis: * P < 0.05, ** P<0.01, *** P<0.001, **** P 
< 0.0001, N.S. not significant, 2-way ANOVA. (A) Effect of Temozolomide (TMZ) on the emergence of macrophage-responsive TICs: 
Tumor cells from young mice (age 23-28 weeks) treated with TMZ or DMSO were stimulated with TAMs derived from TMZ or DMSO 
treated mice. Bars represent mean ± SD. (B) Graph comparing percentage of TAM population derived from young mice treated with TMZ 
or DMSO. Bars represent mean ± SD. (C) Effect of TAMs on chemotherapy-treated TICs: CD34- TICs from old mice were cultured with 
TMZ (200µg/ml) or cisplatin (Cis, 0.5µg/ml) with or without TAMs. Bars represent mean ± SE. (D) Effect of M2-CM on chemotherapy-
treated TICs: CD34- TICs from old mice were cultured with TMZ or cisplatin with or without M2-CM. Bars represent mean ± SE.
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functional disappearance of this tumor cell population. 
This effect is completely reversible, as within 10 days 
of terminating Ki20227 treatment both TAM activity 
(Figure 5E) and the TAM-dependent TIC population had 
recovered (Figure 5F). 
Chemotherapy accelerates the emergence of 
macrophage-responsive TICs
Chemotherapy remains the standard of care for 
many types of cancer, but such treatment can select for 
more aggressive TIC clones [25, 26]. We therefore asked 
whether chemotherapy promotes the emergence of the 
macrophage-responsive TIC sub-population in vivo. We 
exploited the fact that TICs purified from primary tumors 
of RETAAD mice less than 30 weeks old did not respond 
to macrophage stimulation (Figure 4A) to enable us to 
detect any increases in TIC responsiveness as a result of 
chemotherapy. After three doses of temozolamide (TMZ), 
TICs from young mice (< 28 weeks) became responsive 
to stimulation of sphere-formation by TAMs derived from 
either control (DMSO-) or TMZ-treated mice (Figure 6A). 
Remarkably, TMZ also increased the stimulatory activity 
of the TAMs such that even normally unresponsive 
TICs purified from DMSO-treated mice responded to 
TAMs purified from TMZ-treated mice. Furthermore, 
chemotherapy increased the percentage of CD68+ TAMs 
within the tumor (Figure 6B). When TICs from untreated 
mice were exposed to TMZ or another chemotherapy drug, 
cisplatin in vitro, sphere formation was reduced by more 
than 50% (Figure 6C), but TAMs protected the CD34- 
TICs from these adverse effects. M2-CM also protected 
CD34- TICs from TMZ and cisplatin treatments (Figure 
6D). These results demonstrate that chemotherapy recruits 
macrophages into the tumor, accelerates the development 
of TAM-responsive TICs in vivo and that TAMs also 
protect these TICs from chemotherapy.
Macrophages stimulate melanosphere formation 
via TGFβ and the Arginase pathway
Our data indicate that activated M2-like 
macrophages stimulate sphere formation from CD34- 
TICs via secreted factor(s) (Figure 3E and F). TAMs 
from RETAAD tumors contain high levels of Tgfb 
mRNA compared to tumor cells (Figure 7A). As TGFβ 
is well known to regulate tumor growth and metastasis 
[27], and supports the maintenance of stem cells [28], we 
hypothesized that TAM-derived TGFβ might be involved 
in promoting CD34- TIC survival. To test this hypothesis 
we inhibited TGFβ signaling in our melanosphere assays 
using either SD208 [29], a small molecule TGFβ receptor 
kinase inhibitor, or a neutralizing antibody against 
TGFβ. Both inhibitors abolished the sphere stimulatory 
activity of TAMs, without affecting sphere formation in 
the absence of TAMs (Figure 7B). Both inhibitors also 
abolished the stimulatory effect of BMDM derived M2-
CM when added directly to the sphere culture (Figure 
7C), showing that TGFβ is present in the M2-CM and 
that the TICs must be responding via the TGFβ receptor. 
Accordingly, stimulation of TICs with recombinant TGFβ 
increased melanosphere formation in a dose-dependent 
manner (Figure 7D). Interestingly, M2-BMDM pretreated 
with SD208 or anti-TGFβ antibody generate CM that no 
longer stimulate sphere formation (Figure 7C). Therefore, 
in addition to direct effects on the TICs, TGFβ also acts 
upon the TAMs to enable downstream production of 
additional soluble factors that contribute to stimulation of 
sphere formation by TICs. Smad3 is a transcription factor 
activated by TGFβ and Smad3 knockout (Smad3KO) 
mice have defective TGFβ signaling [30]. Accordingly, 
M2-BMDM and M2-CM derived from Smad3KO mice 
were unable to stimulate melanosphere formation by 
CD34- TICs (Figure 7E and Supplemental Figure S6A). 
This confirms that signaling downstream of TGFβ within 
macrophages is required for production of additional 
stimulatory factors. Two known functions of TGFβ are 
auto-regulation [31] and regulation of Arginase 1 (Arg1) 
activity [32], leading to production of polyamines that are 
essential for cell growth and differentiation. We analyzed 
CM from wild-type (WT) and Smad3KO M2-BMDMs 
and found no significant difference in TGFβ concentration 
(Supplemental Figure S6B). However Smad3KO cells had 
significantly lower Arg1 activity (Figure 7F).
The production of polyamines via Arginase 1 
can stimulate tumor growth [33], and TAMs from 
RETAAD tumors expressed high levels of Arg1 (Figure 
8A). To determine whether Arg1 activity and the 
associated production of polyamines contributed to TAM 
stimulation of sphere formation from CD34- TICs, we 
used two inhibitors of this pathway: L-norvaline blocks 
Arg1 activity by competing with the Arg1 substrate 
L-arginine, while difluoromethyl ornithine (DFMO) 
inhibits ornithine decarboxylase, an enzyme downstream 
of Arg1 that converts L-ornithine to polyamines. Both 
inhibitors specifically blocked the stimulatory effect of 
TAMs without affecting baseline sphere formation by 
TICs (Figure 8B). Both inhibitors also eliminated the 
stimulatory effect of M2-CM when BMDM were treated 
prior to CM generation (Figure 8C). When the inhibitors 
were added to untreated M2-CM during sphere culture, 
the stimulatory effect of M2-CM was reduced slightly. 
This shows that both inhibitors predominantly inhibit 
the macrophage Arg1 pathway, but may also act directly 
on the tumor cells. To avoid the non-specific activity 
of these inhibitors on the tumor cells, we used M2-
polarized BMDM from mice with macrophage-specific 
deletion of Arg1. The Arg1fl/fl; LysMcre (LCArg) mice 
lack Arg1 expression in macrophages and neutrophils, 
while the Arg1fl/fl; Tie2cre (TCArg) mice lack Arg1 in all 
hematopoietic lineage cells [34]. While the M2-BMDM 
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from the Arg1fl/fl control mice stimulated TIC sphere 
formation normally, both the LCArg and TCArg mutant 
M2-BMDMs no longer stimulated sphere formation from 
CD34- TICs (Figure 8D). Similarly, CM derived from 
these mutant BMDMs showed no stimulatory effect but 
contained normal levels of TGFβ (Supplemental Figure 
S6C and D). Arg1 activity in both mutant BMDMs was 
severely reduced (Supplemental Figure S6E), confirming 
that Arg1 activity is essential for macrophages to stimulate 
sphere formation. Moreover, addition of exogenous 
polyamines to TICs, specifically spermine and spermidine, 
recapitulated the stimulatory effect of TAMs and M2-CM 
on sphere formation (Figure 8E). The involvement of 
Arg1 is also confirmed when we looked at the effect of 
TMZ treatment in vivo and found that TMZ significantly 
increased the expression of Arg1 in TAMs (Supplementary 
Figure S7A) correlating with the increased stimulatory 
effect of the TAMs (Figure 6A). Conversely, inhibition of 
CD115 using Ki20227 in vivo and in vitro, reduced the 
expression and activity of Arg1 (Supplementary Figure 
S7B – D) correlating with reduced TAM activity (Figures 
3C and 5D). The effect of anti-CD115 antibody in vitro is 
similar, but its effect in vivo is likely due to the reduction 
in macrophage numbers rather than activity (Supplemental 
Figure S5B and C). These treatments did not alter the 
expression of TGFβ (Supplementary Figure S7E – G).
Figure 7: Macrophages stimulate melanosphere formation via TGFβ. For panels (B) to (E), data are expressed as fold change 
in sphere-forming efficiency relative to untreated CD34- TICs. Statistical analysis: * P<0.05, ** P<0.01, *** P<0.001, **** P < 0.0001. 
(A) Graph comparing the Log2 expression of the tgfb gene relative to GAPDH in TAMs and CD34- TICs. Bars represent mean ± SD with 
each point representing cells from one mouse, two-tailed Mann-Whitney test. (B) Effect of TGFβ inhibitors on the stimulatory effect of 
TAMs: Anti-TGFβ antibody (1µg/ml) and SD208 (1µM) were added to CD34- TIC cultures with or without TAMs for the duration of the 
experiment. Bars represent mean ± SE, 2-way ANOVA. (C) Effect of TGFβ inhibitors on the stimulatory effect of M2-CM: Anti-TGFβ 
and SD208 were either added to the BMDM prior to CM generation (SD208 > CM, α-TGFβ > CM) or added to the CM during sphere 
culture (CM+SD208, CM+α-TGFβ). Bars represent mean ± SE. Line above bars represents comparison between M2-CM and each of 
the treatments, 1-way ANOVA. (D) Graph showing the dose-dependent stimulatory effect of TGFβ on sphere formation. Bars represent 
mean ± SE. Line above bars represent analysis of linear trend, 1-way ANOVA. (E) Effect of M2-BMDM derived from tumor-bearing mice 
(RET+), wild-type mice (WT) and Smad3 knockout mice (SMAD3KO) on sphere formation. Bars represent mean ± SE, 1-way ANOVA. 
(F) Comparison of Arg1 activity within WT and SMAD3KO M2-BMDM reflected by the amount of urea production. Bars represent mean 
± SD, two-tailed Mann-Whitney test.
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Paradoxically, addition of TGFβ or polyamines alone 
was sufficient to stimulate sphere formation yet inhibiting 
either abolished the TAM and M2-CM sphere-stimulatory 
effects. This suggests that under normal conditions TAMs 
produce limited amounts of each molecule such that 
both are necessary to stimulate melanosphere formation. 
Accordingly, sub-stimulatory amounts of both TGFβ (5pg/
ml) and spermidine (5pM) synergized to achieve sphere 
stimulation (Figure 8F). Furthermore, inhibition of TGFβ 
signaling by SD208 prevented both this synergy of TGFβ 
and spermidine, and also prevented sphere stimulation 
by higher dose spermidine alone (Figure 8G), indicating 
that spermidine signaling is dependent on an intact TGFβ 
pathway.
DISCUSSION
Disease progression and resistance to treatment 
has been attributed to TICs in several types of cancer. 
Despite recognition of the intimate relationship between 
the immune system and tumor progression, to date, TICs 
have mostly been studied in immune-deficient xenograft 
models. In the present study, we used immune-competent 
mice that spontaneously develop progressive melanoma 
that recapitulates many important features of the human 
disease. We identified two distinct populations of TICs 
of which the CD34- TIC sub-population was uniquely 
responsive to TAMs, which increased both TIC survival 
and proliferation through the TGFβ and Arginase 
pathways. Although the CD34+ population also efficiently 
initiated tumors in vivo, its relative scarcity means that its 
biological significance is likely to be negligible compared 
Figure 8: Macrophages stimulate melanosphere formation via the Arginase 1 pathway. For panels (B) to (G), data are 
expressed as fold change in sphere-forming efficiency relative to untreated CD34- TICs, bars represent mean ± SE. Statistical analysis: * 
P<0.05, ** P<0.01, *** P<0.001, **** P < 0.0001, N.S. not significant.  (A) Graph comparing the Log2 expression of the Arg1 gene relative 
to GAPDH in TAMs and CD34- TICs. Bars represent mean ± SD, two tailed Mann-Whitney test. (B) Effect of arginase pathway inhibitors 
on the stimulatory effect of TAMs: L-norvaline (L-nor; 20mM) and DFMO (1mM) were added to CD34- TIC cultures with or without 
TAMs for the duration of the experiment, 2-way ANOVA. (C) Effect of arginase pathway inhibitors on the stimulatory effect of M2-CM: 
L-nor and DFMO were either added to the BMDM prior to CM generation (L-nor > CM, DFMO > CM) or added to the CM (CM+L-nor, 
CM+DFMO) during sphere culture, 1-way ANOVA. (D) Effect of M2-BMDM derived from tumor bearing mice (RET+), Arg1fl/fl mice 
(WT), Arg1fl/fl;LysMcre mice (LCArg) and Arg1fl/fl;Tie2cre mice (TCArg) on sphere formation, 1-way ANOVA. (E) Effect of increasing 
concentrations of recombinant polyamines on sphere formation, 2-way ANOVA. (F) Synergistic effect of TGFβ and spermidine (SPD) on 
sphere formation: TGFβ (5pg/ml), spermine (Sper; 5pM) and SPD (5pM) were added individually or in the combinations shown, 2-way 
ANOVA. (G) Effect of TGFβ receptor inhibition on TGFβ- and SPD- stimulated sphere formation: CD34- TICs were cultured alone, with 
TGFβ (5pg/ml) and SPD (5pM), or with SPD (10pM) in the presence or absence of SD208 (1µM), 2-way ANOVA.
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to the CD34- TICs.
Macrophages, specifically TAMs and the related 
subset of M2-/alternatively-activated macrophages 
promote tumor cell proliferation and extravasation at the 
metastatic site [35]. In patients, the number of TAMs are 
generally correlated with poor prognosis [36]. Indeed, a 
recently approved chemotherapeutic agent, trabectedin, 
may reduce tumor growth in part by depleting TAMs 
[37]. Our data reveal that TAMs in the primary tumor also 
promote tumor initiation. Although TAMs do not alter the 
gene expression profile or the tumorigenic ability of TICs, 
they are essential for the survival of TICs as indicated 
by the ability of TAMs to stimulate sphere formation. 
This suggests that the presence of TAMs can increase 
the opportunities for tumor growth to be initiated in vivo. 
The ability of these TAM-responsive TICs to disappear 
with CSF-1R inhibition and recover rapidly upon 
termination of macrophage inhibition suggests that the 
TIC phenotype may be plastic. This is consistent with the 
ability of melanoma cells to switch phenotypes [38], and 
suggest that alterations to the tumor microenvironment 
might change the behavior of tumor cells, including 
TICs. Indeed, chemotherapy induced rapid appearance 
of a macrophage-responsive TIC population in young 
RETAAD mice with early disease, while macrophages 
protect this TIC population from chemotherapy by 
stimulating more sphere formation. TMZ treatment also 
increased Arginase 1 expression and the corresponding 
stimulatory activity of TAMs. Furthermore, chemotherapy 
promotes macrophage infiltration into the tumor (our data 
and ref.[8, 39]) and TAM density correlates with increased 
tumor relapse [40, 41]. Thus, our data suggest that TIC-
macrophage interactions could contribute to relapse after 
chemotherapy. 
An interesting phenomenon that we observed is 
that TICs from young mice (< 30wks) do not respond to 
TAM stimulation. There are several possible explanations 
for this. Firstly, tumors in young mice may be more 
self-sufficient. But as the disease progresses, limitations 
within the tumor microenvironment including nutrient and 
space may force tumor cells to adapt and utilize all the 
available cytokines, including those from TAMs within 
their environment to survive and propagate. Alternatively, 
the TAM-dependent TICs that developed after 30 weeks 
of age may be a new tumor cell clone that did not exist 
previously. More work will be required to elucidate this 
point. 
Using our registry of 285 clinically-characterized 
RETAAD mice we show that the rate of spontaneous 
metastasis development varies with age and that 
metastases occur in two waves. A sharp increase in 
metastases after 30 weeks coincides with the acquisition 
of macrophage responsiveness by CD34- TICs. Currently 
we do not know whether this second wave of metastases 
develop from dormant early disseminated TICs acquiring 
the ability to respond to growth stimuli from macrophages, 
or from new populations of macrophage-responsive 
TIC clones leaving the primary tumor. In any case, 
macrophage inhibition in vivo suppressed the macrophage-
responsive TIC population. Human cancers have similar 
heterogeneous rates of progression [42, 43], suggesting 
some heterogeneity in human TICs as well, and illustrating 
the advantages of using clinically-relevant mouse models 
to dissect these phenomena.
Recent studies showed that tumor-educated 
macrophages can stimulate TICs [6-8]. In contrast, our 
data show that the M2 phenotype, i.e. the production 
of TGFβ and polyamines, is sufficient to stimulate TIC 
survival regardless of tumor exposure since macrophages 
from non-tumor bearing mice also stimulated TIC survival 
(Figure 3D). Thus, the presence of M2 macrophages in 
organs such as the lungs may contribute to their marked 
susceptibility as sites of metastasis by enhancing the 
survival of any disseminated TIC that arrives. We 
have unpublished data indicating that lung-derived 
macrophages, whether from healthy or tumor-bearing 
mice, can stimulate CD34- TICs. Indeed, macrophages 
may even contribute to the attraction of stem cells as 
demonstrated by the ability of macrophages to recruit 
human vessel-associated stem cells for muscle repair [44].
Consistent with the adaptability of tumor cells, we 
found that CD34- TICs use existing trophic pathways 
within their environment, namely TAM-derived TGFβ 
and polyamines, for their survival. The late (>30 weeks of 
age) acquisition of TGFβ/TAM-dependent survival in our 
model is consistent with TGFβ being a tumor suppressor 
during early carcinogenesis but promote tumor growth 
and metastasis with tumor progression [27]. TAM-derived 
TGFβ may also suppress the immune system [45, 46], 
and convert non-TICs to TICs due to its ability to induce 
epithelial-mesenchymal transition (EMT) [47], which in 
turn promotes “stemness” in non-TICs [3, 48], though 
more work will be required to confirm these hypotheses. 
Polyamines are essential for cell growth and are 
frequently dysregulated in cancer [49]; with multiple 
polyamine inhibitors currently in clinical trials as cancer 
treatments [50, 51]. Besides tumor-derived polyamines, 
macrophages are also an important source of polyamines 
within the tumor microenvironment [33, 52]. The 
dependency on TAM-derived polyamines suggests that 
the TICs might lack polyamines or unable to consume 
them without TAM stimulation. The synergism between 
TGFβ and spermidine suggest that TGFβ might regulate 
polyamine uptake similar to its regulation of arginine 
uptake in vascular smooth muscle cells [53], and indicates 
that even in tumors with few infiltrating macrophages, low 
levels of macrophage-derived TGFβ and polyamines could 
contribute to TIC survival and metastasis. 
CAFs are also an important source of TGFβ within 
the tumor microenvironment [54] and can stimulate 
cancer cell stemness [21]. Recent publication showed 
reciprocal interactions between CAFs and macrophages. 
Oncotarget13www.impactjournals.com/oncotarget
CAFs polarizes macrophages to a pro-angiogenic M2 
phenotype while macrophages enhances CAF induced 
tumor invasiveness [22]. However, we did not observe 
any contribution from CAFs during TAM stimulation of 
sphere formation in our study. Thus we speculate that 
the interaction between CAFs and macrophages may 
regulate tumor invasion, but the regulation of tumor 
stemness and tumor initiation by these two cells types 
may be independent events. We have shown that even 
though macrophages from SMAD3KO and LCArg1 
mice produce normal levels of TGFβ they were unable to 
stimulate sphere formation. This again supports the idea 
that synergism with polyamines is necessary and that CAF 
derived TGFβ alone will similarly be unable to stimulate 
TICs.
In conclusion, our results demonstrate that TAMs 
interact specifically with the CD34- TIC population from 
RETAAD tumors, both in vitro and in vivo. We show that 
macrophage-derived TGFβ and polyamines are essential 
for TIC survival and can support their resistance to 
chemotherapeutic drugs. We also show that changes in 
the macrophage-responsiveness of TICs mirror tumor 
progression in vivo and that macrophages may accelerate 
cancer progression in mice with slow rates of tumor 
development. In vivo macrophage inhibition transiently 
suppresses the macrophage-responsiveness of the CD34- 
TIC population, whereas chemotherapy accelerates the 
emergence of TAM-responsive TICs. The identification 
and further characterization of this macrophage-responsive 
TIC population will facilitate development of improved 
therapies for human cancers.
MATERIAL AND METHODS
Mice
Animal care and experimental procedures were 
approved by the Singapore IACUC under protocols 
120742 and ARF-SBS/NIE-A0167-AZ, or performed 
under Animal Study Proposal LPD16E approved by 
the NIAID IACUC. RETAAD mice were generated as 
described [55]. Male and female mice 23-60 weeks of age 
were used for experiments. Smad3KO mice [56], Arg1fl/
fl; LysMcre mice and Arg1fl/fl; Tie2cre mice [34] were 
generated as described.
Cell culture
Tumors were dissociated with collagenase A (1mg/
ml) and DNase I (0.1mg/ml; Roche) and cultured in 
stem cell medium [DMEM/F12 (1:1), 1% penicillin/
streptomycin, B27 supplement (Invitrogen), 10ng/ml 
bFGF and 20ng/ml EGF (Peprotec)] at 4000 cells/cm2 
in ultra-low attachment culture wells (Corning). Culture 
plates were not disturbed during the culturing period to 
avoid sphere formation by aggregation. Spheres greater 
than 30µm in diameter were counted 5-7 days after cell 
seeding. Immune cells were added at a ratio of 1:50 to 
tumor cells and remained for the duration of the culture.
Cell selection
TIC and immune cell populations were harvested 
from the same mice for each experiment. CD45+ 
immune cells were depleted from the tumor with anti-
CD45-PE antibody and the anti-PE EasySep selection 
kit (StemCell). Tumor cell sub-populations were sorted 
by flow cytometry using CD34-biotin (eBioscience), 
anti-CD271 (Millipore) and CD45-FITC (Biolegend) 
antibodies followed by streptavidin-PE and anti-rabbit 
PECy7 (Invitrogen) antibodies. Immune cell population 
were sorted using CD45, CD3, CD4, CD8, NK1.1, CD19, 
CD11b (Biolegend), and CD68 (AbDserotec) conjugated 
to appropriate fluorophores. Stromal cell populations 
were sorted using CD31-PECy7 and PDGFRα-APC 
(Biolegend).
In vivo CD115 inhibition
Mice underwent gavage with Ki20227 (30mg/kg/
day in 0.05% methylcellulose; Accelachembio) over 
10 days. The anti-CD115 monoclonal antibody [clone 
AFS98; [57]] was purified from culture supernatant of 
AFS98 hybridoma. 3mg of antibody was injected intra-
peritoneally on days 0, 1 and 7. Mice were sacrificed on 
day 10.
Transplantation of spheres into mice
Melanospheres (100 per mouse) were manually 
picked under the microscope and re-suspended in 100µl 
of PBS for retro-orbital injection into Rag1 mice. Mice 
were sacrificed after 8 weeks and the lungs harvested for 
immunohistochemistry. 
BMDM and conditioned medium
Bone marrow cells were cultured in complete 
medium [DMEM, 10% FBS, 1% penicillin/streptomycin, 
1% L-glutamine, 30% L929 cell-conditioned medium] for 
5 days and polarized towards M1 (100ng/ml LPS; Sigma, 
and 20ng/ml IFN-γ; Miltenyi) or M2 (20ng/ml IL-4; 
Miltenyi) phenotypes with cytokines overnight. BMDM-
conditioned medium (CM) was generated by replacing 
complete medium with stem cell medium and harvesting 
after 24 hours and used at 1/10th of stem cell medium. 
Inhibitors were added during BMDM polarization and 
cells were washed thoroughly prior to CM generation. 
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Inhibitors and stimulators
All reagents were added at the start of the sphere 
culture and remained for the duration of the experiment. 
Ki20227, SD208 and DFMO (Tocris), L-norvaline, 
putrescine, spermine and spermidine (Sigma), TGFβ 
(R&D systems), anti-TGFβ (clone 1D11, R&D 
Systems) and anti-CD115 antibodies were added at 
the concentrations stated on the respective figures. For 
pretreatment experiments, cells were incubated with anti-
CD115 (1µg/ml) for 1 hour then washed thoroughly prior 
to culturing. Temozolamide and cisplatin (Sigma) were 
used at 200µg/ml and 0.5ug/ml respectively in vitro. For 
in vivo chemotherapy, temozolamide (3mg) was injected 
intra-peritoneally on days 0, 1 and 2. Mice were sacrificed 
on day 7.
Statistical analysis
Graphs and statistical analysis were generated using 
Graphpad Prism 6 software. Tests applied are indicated in 
the figure legends. Two-tailed non-parametric tests (Mann-
Whitney for unpaired and Wilcoxon matched-pair test for 
paired experiments) were used for comparison between 
two groups. One way ANOVA was used to compare 
multiple groups with one experimental parameter while 
a two-way ANOVA was used to compare multiple groups 
with two experimental parameters. 
Additional experimental procedures can be found in 
the Supplemental section.
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